Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hurler-Scheie,Scheie form of MPS I, of Hurler 2 years after hematopoietic stem cell transplantation~* Spinal cord compression~* Age greater than 8 years~* Able to provide legal informed consent~* Aware of clinical treatment option of observation without treatment or surgical decompression~* Negative urine pregnancy test at screening (non-sterile females of child-bearing potential only)~* Currently using two acceptable methods of birth control (non-sterile females of child-bearing potential who are sexually active only)~* Willing and able to comply with study procedures~Exclusion Criteria:~* Severe (Hurler) form of MPS I~* Desires surgical or medical treatment of spinal cord compression~* Spinal cord compression that warrants immediate surgical intervention~* Pregnancy or lactation~* Hematopoietic stem cell transplantation within 2 years of study enrollment~* Receipt of an investigational drug within 30 days of enrollment~* Infusion reactions to laronidase that required medical intervention, prophylaxis, or altered enzyme administration~* Significant anti-iduronidase antibody titer~* Recent initiation of intravenous laronidase (within past 6 months)~* Presence of cervical subluxation or similar external pathology as the major cause of cord compression symptoms for which surgical intervention should be immediately undertaken

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intrathecal laronidase (Type: EXPERIMENTAL): laronidase dose 1.74 mg, route intrathecal, frequency every 30 days, duration three months

Based on this trial design, predict the completion outcome and termination type (if applicable).